Wong CR, Nguyen MH, Lim JK. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(37): 8294-8303 [PMID: 27729736 DOI: 10.3748/wjg.v22.i37.8294]
Corresponding Author of This Article
Joseph K Lim, MD, Associate Professor, Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520, United States. joseph.lim@yale.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 7, 2016; 22(37): 8294-8303 Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8294
Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
Carrie R Wong, Mindie H Nguyen, Joseph K Lim
Carrie R Wong, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, United States
Mindie H Nguyen, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94304, United States
Joseph K Lim, Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520, United States
Author contributions: Wong CR drafted the manuscript, contributed to the conception and design, and made revisions for resubmission; Nguyen MH and Lim JK contributed to the conception and design and provided critical revisions of the manuscript.
Conflict-of-interest statement: There is no conflict of interest associated with any of the authors.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Joseph K Lim, MD, Associate Professor, Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520, United States. joseph.lim@yale.edu
Telephone: +1-203-7376063 Fax: +1-203-7857273
Received: April 29, 2016 Peer-review started: May 4, 2016 First decision: July 13, 2016 Revised: August 3, 2016 Accepted: August 23, 2016 Article in press: August 23, 2016 Published online: October 7, 2016 Processing time: 154 Days and 2.1 Hours
Core Tip
Core tip: This review summarizes the epidemiology, pathogenesis, disease presentation, demand and receipt of curative treatment, and post-treatment outcomes of hepatocellular carcinoma (HCC) in nonalcoholic fatty liver disease (NAFLD). The review highlights the developing understanding of NAFLD-HCC pathogenesis, which has broadened to include genetic polymorphisms, adaptive immune responses, and cellular regenerative pathways using hepatic progenitor cell populations. While NAFLD-HCC has been described to have poorer prognosis as compared with other HCC etiologies, this review features summarized evidence that disease-free and survival rates among patients with NAFLD-HCC are comparable and potentially favorable after receipt of curative treatment.
